Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering

FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the closing of its previously announced underwritten public offering of 12,555,555 units (“Units”), at a price to the public of $0.45 per Unit for aggregate gross proceeds of approximately $5.7 million, prior to deducting underwriting discounts, commissions, and other estimated offering expenses. Each Unit consists of one share of common stock, par value $0.005 per share (the “Common Stock”), one warrant with a one-year term to purchase one share of Common Stock at an exercise price of $0.45 per share (the “One-Year Warrants”), and one warrant with a five-year term to purchase one share of our Common Stock at an exercise price of $0.5625 per share (the “Five-Year Warrants”). The shares of Common Stock, the One-Year Warrants, and the Five-Year Warrants are immediately separable and will be issued separately and uncertificated. In connection with the offering, the underwriters have partially exercised their option to purchase an additional 1,883,333 One-Year Warrants and 1,883,333 Five-Year Warrants at the public offering price of $0.01 per One-Year Warrant and $0.01 per Five-Year Warrant, less the underwriting discount per warrant, solely to cover over-allotments, if any.